Hayley M. Sabol

Federal Grant PI

Researcher

University of Arkansas for Medical Sciences

faculty

6 h-index 66 pubs 100 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Hayley M. Sabol's research focuses on the molecular mechanisms underlying bone destruction and tumor growth in multiple myeloma, as well as the role of cellular senescence in cancer metastasis. She has investigated signaling pathways, including Notch, CXCL12, CCL3, and HMGB1, that contribute to the tumor microenvironment in multiple myeloma. Her work has explored how these interactions promote tumor growth and chemoresistance, and how targeting specific pathways can impact these processes.

In addition to her work on multiple myeloma, Sabol has also studied the role of senescent osteocytes in bone destruction associated with breast cancer metastasis. Her research has utilized single-cell transcriptomic analysis to identify these senescent cells and understand their contribution to bone pathology. Sabol has received federal funding from the NIH/National Cancer Institute for her work on targeting Notch3 for the treatment of multiple myeloma.

Her collaborations include numerous researchers at the University of Arkansas for Medical Sciences, such as Aric Anloague, Olivia Reyes‐Castro, Japneet Kaur, and Elena Ambrogini. Sabol leads a research group and has published 66 papers with a total of 100 citations and an h-index of 6.

Metrics

  • h-index: 6
  • Publications: 66
  • Citations: 100

Selected Publications

  • Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025) DOI
  • A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024) DOI
  • Senolytics deplete senescent osteocytes and improve bone health in metastatic breast cancer (2024) DOI
  • Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis (2024) DOI
  • A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma (2024) DOI
  • Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma (2023) DOI
  • Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity (2023) DOI
  • Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction (2022) DOI
  • Abstract 5675: Pathological crosstalk between osteocytes and breast cancer cells in bone metastasis (2022) DOI
  • Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction (2022) DOI
  • The multifunctional role of Notch signaling in multiple myeloma (2021) DOI

Federal Grants 1 $39,248 total

NIH/National Cancer Institute Contact PI Jul 2023 - Jun 2025

Targeting Notch3 for the treatment of multiple myeloma

National Cancer Institute $39,248 F31

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics